Symbiosis Honoured with Prestigious King’s Award for Enterprise for International Trade

Symbiosis Pharmaceutical Services (Symbiosis), a global biopharmaceutical Contract Manufacturing Organisation (CMO) specialising in the sterile fill finish of injectable drug products has been awarded a 2025 King’s Award for Enterprise in the International Trade category, the UK’s highest official accolade for British businesses.

This prestigious recognition celebrates Symbiosis’ outstanding success in international markets, underlining its role as a trusted global partner in the manufacture of life-saving therapies. With clients across North America, Europe and the Asia-Pacific region, Symbiosis has experienced sustained growth, driven by its strategic focus of serving the global biotechnology and pharmaceutical industries.

The King’s Awards for Enterprise are granted annually by His Majesty King Charles III and are regarded as the pinnacle of British business achievement. Symbiosis joins an exclusive group of only 197 UK organisations to receive the recognition in 2025, gaining the right to display the King’s Award emblem for the next five years, symbolising excellence and credibility on the world stage.

“We are greatly honoured to receive the Kings Award for Enterprise” said Colin MacKay, CEO of Symbiosis. This achievement reflects the incredible dedication and expertise of the whole Symbiosis team, and the trust placed in us by our international clients to help bring their life-changing medicines to patients around the world. It’s a proud moment for our company and for both the UK and Scottish life sciences sector”.

This award not only acknowledges Symbiosis’ commercial performance overseas, but also its ongoing contribution to the UK’s global reputation for manufacturing excellence, and quality in the life sciences sector.

As Symbiosis looks ahead, the company remains committed to expanding its service offering and its global reach by supporting biotechnology and pharmaceutical clients in the manufacture and supply of complex injectable medicines that improve and save lives.

The King’s Award, previously known as The Queen’s Award for Enterprise, was renamed in 2023 to continue Queen Elizabeth II’s legacy of celebrating excellence in the UK business community.